Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital.
Arch Dermatol Res
; 314(3): 301-305, 2022 Apr.
Article
in En
| MEDLINE
| ID: mdl-33094412
ABSTRACT
Hidradenitis suppurativa (HS) is a difficult-to-treat chronic relapsing skin disease, which greatly impacts the quality of life. To bring forward real-life challenges in the decision-making process regarding HS treatment. A retrospective observational study was performed with treatment-related data derived from the HS archive of tertiary hospital-based First Department of Dermatology and Venereology of Aristotle University, Greece. Data were available for 121 patients, 63 men (52.7%) and 58 women (47.93%) with a mean age of 38 years. Doxycycline 100 mg twice daily for 1-2 weeks and then once daily for up to a total of 12 weeks was the most popular treatment choice (80 patients, 66.12%), administered for mild-to-moderate disease. Biologics were the second most frequently prescribed treatment, reserved for moderate-to-severe disease (adalimumab 26 patients, 14.88%, infliximab 2 patients, 1.65%). All in all, a wide variety of treatment regimens were implemented, with various combinations of topical and systemic agents. Real-life practice reflects the relative paucity of high-quality evidence regarding HS treatment and the absence of a unanimously preferable therapeutic option, leaving both dermatologists and patients defenceless against disease progress and sequelae.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hidradenitis Suppurativa
/
Dermatologic Agents
/
Adalimumab
/
Infliximab
Type of study:
Observational_studies
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Adult
/
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
Arch Dermatol Res
Year:
2022
Document type:
Article
Affiliation country:
Greece